Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zealand Pharma sets up CSAB

This article was originally published in Scrip

Executive Summary

Zealand Pharma, a Danish biopharmaceutical company discovering and developing innovative peptide drugs has appointed a new clinical and scientific advisory board. Dr Alain Munoz, a Zealand board member and Dr Christian Groendahl, Zealand's CSO, will jointly chair the CSAB. Other members include: Dr Bernard Charbonnel, professor of endocrinology and metabolic diseases at the University of Nantes; Dr Richard Pratley, medical director of the Florida Hospital Diabetes Institute; Dr Paul Dorian, department director for the University of Toronto's division of cardiology and staff electrophysiologist at St Michael's Hospital; Dr Ake Lernmark, professor of experimental diabetes at Lund University in Malmo, Seden and professor emeritus of medicine at the University of Washington; and Dr Gert Van Assche, professor of medicine at the University of Leuven, Belgium.

You may also be interested in...



Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.

Topics

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel